Trial Profile

Early Clinical Development of a Live, Attenuated Combination Vaccine Against Shigella and ETEC Diarrhoea: Phase 1b Clinical Trial of ShigETEC Vaccine in Bangladeshi Adults and Three Paediatric Age Groups

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escherichia coli/Shigella oral vaccine-Eveliqur Biotechnologies (Primary)
Indications Traveller's diarrhoea
Focus Adverse reactions
Sponsors Eveliqure Biotechnologies

20 May 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2025.
20 May 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Oct 2025.
15 Jul 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com